Doxorubicin-Loaded Cerium Oxide Nanoparticles Suppress Cell Proliferation, Migration and Invasion of Triple-Negative Breast Cancer Cells
ACS Omega · 28.07.2026 · 11 (29) · 44029-44043
DOI: 10.1021/acsomega.6c03856 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 16.07.2026. Verfasst von Anongnat Wongpan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kasetsart University, National Research Council of Thailand, Mahidol University.
Abstract (Originalsprache)
Cerium oxide nanoparticles (Ceria NPs), possessing redox activity, exhibit selective anticancer effects and hold significant promise for cancer therapy. In this study, Ceria NPs were synthesized via a hydrothermal method and characterized for stability in a biological environment. Optimal colloidal dispersion was achieved in 10% fetal bovine serum (FBS) with a hydrodynamic diameter of 56.3 nm. Ceria NPs exhibited strong antioxidant activity tested by DPPH assay and showed high biocompatibility, displaying minimal toxicity toward normal breast epithelial cells (MCF-10A) while exerting cytotoxic effects on breast cancer cells (IC50 = 363.0 ± 71.89 μg mL–1 for MCF-7 and 547.9 ± 0.14 μg mL–1 for MDA-MB-231). Given their limited standalone cytotoxicity but favorable selectivity, Ceria NPs were employed as a nanocarrier for doxorubicin (Dox) to enhance anticancer efficacy while potentially reducing systemic side effects. Ceria-Dox markedly enhanced cytotoxic efficacy, reducing IC50 values to 129.3 ± 21.86 μg mL–1 in MCF-7 and 33.2 ± 1.37 μg mL–1 in MDA-MB-231 cells, with more pronounced effects in TNBC cells while maintaining low toxicity toward normal cells. Live/dead staining confirmed a dose-dependent cytotoxicity, while the transwell assay demonstrated strong inhibition of migration and invasion in TNBC cells treated with Ceria-Dox. These findings highlight Ceria-Dox as a colloidally stable nanoplatform that delivers dual therapeutic actions, including potent cytotoxicity and suppression of metastatic potential, underscoring its promise for treating breast cancer, particularly aggressive subtypes such as triple-negative breast cancer.
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
- Department of Chemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand.
- Synchrotron Light Research Institute (Public Organization), 111 University Avenue, Muang, Nakhon Ratchasrima 30000, Thailand.
- Center for Advanced Studies in Nanotechnology for Chemical, Food and Agricultural Industries, KU Institute for Advanced Studies, Kasetsart University, Bangkok 10900, Thailand.
- Department of Mathematics, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
ORCID-Profile: Duangkamon Baowan, Kanlaya Prapainop Katewongsa
Förderung
- Kasetsart University
- National Research Council of Thailand
- Mahidol University
- Kasetsart University Research and Development Institute
Zitieren
APA
Wongpan, A., Keo, S., Siri, W., Chanlek, N., Luksirikul, P., Baowan, D., & Katewongsa, K. P. (2026). Doxorubicin-Loaded Cerium Oxide Nanoparticles Suppress Cell Proliferation, Migration and Invasion of Triple-Negative Breast Cancer Cells. ACS Omega, 11(29), 44029-44043. https://doi.org/10.1021/acsomega.6c03856
Vancouver
Wongpan A, Keo S, Siri W, Chanlek N, Luksirikul P, Baowan D, et al. Doxorubicin-Loaded Cerium Oxide Nanoparticles Suppress Cell Proliferation, Migration and Invasion of Triple-Negative Breast Cancer Cells. ACS Omega. 2026;11(29):44029-44043. doi:10.1021/acsomega.6c03856
BibTeX
@article{Wongpan2026,
author = {Wongpan, Anongnat and Keo, Sereysonita and Siri, Wiradet and Chanlek, Narong and Luksirikul, Patraporn and Baowan, Duangkamon and Katewongsa, Kanlaya Prapainop},
title = {Doxorubicin-Loaded Cerium Oxide Nanoparticles Suppress Cell Proliferation, Migration and Invasion of Triple-Negative Breast Cancer Cells},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {29},
pages = {44029--44043},
doi = {10.1021/acsomega.6c03856}
}
EUVIMED